Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder

Psychiatry Research

Volumn 149, Issue 1-3, 2007, Pages 195-200

  Papakostas, George I ^a   Petersen, Timothy ^a   Sklarsky, Katherine G ^a   Nierenberg, Andrew A ^a   Alpert, Jonathan E ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Fluoxetine; Onset; Residual; Symptom

Indexed keywords

FLUOXETINE;

ADULT; AGED; ANXIETY; ARTICLE; BECK HOPELESSNESS SCALE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEASUREMENT; MENTAL PATIENT; OUTPATIENT; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANGER; ANXIETY DISORDERS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FLUOXETINE; HOSTILITY; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846227445     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2006.03.014     Document Type: Article

References (39)

1. Beck A.T., and Steer R.A. Manual for the Beck Hopelessness Scale (1988), Psychological Corp, San Antonio, TX
2. Bolo N.R., Hode Y., Nedelec J.F., Laine E., Wagner G., and Macher J.P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23 (2000) 428-438
3. Boyer P., Tassin J.P., Falissart B., and Troy S. Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression. Journal of Clinical Pharmacy and Therapeutics 25 (2000) 363-371
4. Casper R.C., Katz M.M., Bowden C.L., Davis J.M., Koslow S.H., and Hanin I. The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. Journal of Affective Disorders 31 (1994) 151-164
5. Cook I.A., Leuchter A.F., Morgan M., Witte E., Stubbeman W.F., Abrams M., Rosenberg S., and Uijtdehaage S.H. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 27 (2002) 120-131
6. Coryell W., Coppen A., Zeigler V.E., and Biggs J.T. Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of 2 patient samples. Psychological Medicine 12 (1982) 135-139
7. Dunlop S.R., Dornseif B.E., Wernicke J.F., and Potvin J.H. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacology Bulletin 26 (1990) 173-180
8. Dunn O.J. Multiple comparisons among means. Journal of American Statistics Association 56 (1961) 52-64
9. Goodnick P.J., Fieve R.R., Peselow E.D., Barouche F., and Schlegel A. Double-blind treatment of major depression with fluoxetine: use of pattern analysis and relation of HAM-D score to CGI change. Psychopharmacology Bulletin 23 (1987) 162-163
10. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 23 (1960) 56-62
11. Iosifescu D.V., Greenwald S., Devlin P., Alpert J.E., Hamil S., and Fava M. Frontal EEG Predicts Clinical Response to SSRI Treatment in MDD (2004), New Clinical Drug Evaluation Unit National Meeting, Phoenix, Arizona
12. Katz M.M., Koslow S.H., Maas J.W., Frazer A., Bowden C.L., Casper R., Croughan J., Kocsis J., and Redmond Jr. E. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychological Medicine 17 (1987) 297-309
13. Katz M.M., Tekell J.L., Bowden C.L., Brannan S., Houston J.P., Berman N., et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29 (2004) 566-579
14. Kellner R. A symptom questionnaire. Journal of Clinical Psychiatry 48 (1987) 268-274
15. Khan A., Cohen S., Dager S., Avery D.H., and Dunner D.L. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. Journal of Affective Disorders 17 (1989) 33-38
16. Kirsch I. Are drug and placebo effects in depression additive?. Biological Psychiatry 47 (2000) 733-735
17. Laska E.M., and Siegel C. Characterizing onset in psychopharmacological clinical trials. Psychopharmacology Bulletin 31 (1995) 29-35
18. Leuchter A.F., Cook I.A., Witte E.A., Morgan M., and Abrams M. Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry 159 (2002) 122-129
19. Mayberg H.S., Brannan S.K., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., and Jarabek P.A. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biological Psychiatry 48 (2000) 830-843
20. Mayberg H.S., Silva J.A., Brannan S.K., Tekell J.L., Mahurin R.K., McGinnis S., and Jarabek P.A. The functional neuroanatomy of the placebo effect. American Journal of Psychiatry 159 (2002) 728-737
21. McGrath P.J., Stewart J.W., Petkova E., Quitkin F.M., Amsterdam J.D., Fawcett J., Reimherr F.W., Rosenbaum J.F., and Beasley Jr. C.M. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. Journal of Clinical Psychiatry 6 (2000) 518-524
22. Nagayama H., Nagano K., Ikezaki A., and Tashiro T. Prediction of efficacy of antidepressant by 1-week test therapy in depression. Journal of Affective Disorders 23 (1991) 213-216
23. Nierenberg A.A., McLean N.E., Alpert J.E., Worthington J.J., Rosenbaum J.F., and Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. American Journal of Psychiatry 152 (1995) 1500-1503
24. Nierenberg A.A., Farabaugh A.H., Alpert J.E., Gordon J., Worthington J.J., Rosenbaum J.F., and Fava M. Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry 157 (2000) 1423-1428
25. Nierenberg A.A., Quitkin F.M., Kremer C., Keller M.B., and Thase M.E. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 29 (2004) 1012-1018
26. Papakostas G.I., Petersen T., Denninger J.W., Tossani E., Pava J.A., Alpert J.E., et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. Journal of Clinical Psychopharmacol 24 5 (2004) 507-511
27. Pollock B.G., Perel J.M., Kupfer D.J., Bowler K.A., and Miewald J.M. Early response patterns associated with successful clomipramine treatment. Journal of Clinical Psychopharmacology 13 (1993) 442-447
28. Posternak M.A., and Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry 66 2 (2005) 148-158
29. Quitkin F.M., Rabkin J.G., Ross D., and Stewart J.W. Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry 41 (1984) 782-786
30. Quitkin F.M., Rabkin J.D., Markowitz J.M., Stewart J.W., McGrath P.J., and Harrison W. Use of pattern analysis to identify true drug response. A replication. Archives of General Psychiatry 44 (1987) 259-264
31. Sonawalla S.B., Hutchins A.C., Delgado M.L., Johnson M.W., Worthington J.J., Alpert J.E., and Fava M. Onset of response to fluoxetine as assessed by the symptom questionnaire. American Psychiatric Association Annual Meeting, New Orleans (2001)
32. Spitzer R.L., Williams J.B.W., Gibbon M., and First M. Structured Clinical Interview for DSM-III-R-Patient Edition (SCID-P) (1989), New York State Psychiatric Institute, Biometrics Research Department, New York
33. Stassen H.H., Kuny S., and Hell D. The speech analysis approach to determining onset of improvement under antidepressants. European Neuropsychopharmacology 8 (1998) 303-310
34. Stassen H.H., Angst J., and Delini-Stula A. Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry 32 (1999) 56-60
35. Stewart J.W., Quitkin F.M., McGrath P.J., Amsterdam J., Fava M., Fawcett J., Reimherr F., Rosenbaum J., Beasley C., and Roback P. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Archives of General Psychiatry 55 (1998) 334-343
36. Szegedi A., Muller M.J., Anghelescu I., Klawe C., Kohnen R., and Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Journal of Clinical Psychiatry 64 (2003) 413-420
37. Tollefson G.D., and Holman S.L. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. International Clinical Psychopharmacology 9 (1994) 245-250
38. Tomarken A.J., Dichter G.S., Freid C., Addington S., and Shelton R.C. Assessing the effects of bupropion SR on mood dimensions of depression. Journal Affective Disorders 78 (2004) 235-241
39. Worthington J., Fava M., Davidson K., Alpert J., Nierenberg A.A., and Rosenbaum J.F. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacology Bulletin 31 (1995) 223-226